This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genzyme CEO Defends Tenure as Icahn Lurks

SAN FRANCISCO ( TheStreet) -- Embattled Genzyme (GENZ) CEO Henri Termeer told a packed room of investors Tuesday that he accepted responsibility for the manufacturing problems that have crippled the biotech firm this year. But he also insisted that he's the best man to lead the company's recovery.

"I accept with great humility that these manufacturing interruptions have happened under my watch," said Termeer, in response to my question about why he should remain the company's chief executive.

Henri Termeer
Genzyme's CEO Henri Termeer
Termeer spent a good bit of his 30-minute breakout session at the J.P. Morgan Healthcare Conference outlining the steps Genzyme is taking to recover from a year's worth of manufacturing problems that caused drug shortages, a drop in earnings and a plunging stock price.

But investors I spoke with remain unconvinced that Termeer can get the job done, which may be why Genzyme's stock price seems to move higher only when the talk turns to speculation about proxy fights and management housecleaning.

Towards that end, one investor in the breakout session asked Termeer if Genzyme has had any contact with billionaire hedge fund manager and activist shareholder Carl Icahn.

"We've had no discussions with Mr. Icahn," replied Termeer. "No contact."

Icahn owns 1.5 million Genzyme shares as of the third quarter and speculation is building that he's buying more stock to prepare for a proxy fight.

Alex Denner, Icahn's biotech lieutenant, was spotted in the room during Termeer's talk but had nothing to say publicly. (More than a few people turned to glance at Denner after Termeer responded to the Icahn question, as if expecting him to stand up and counterpunch.)

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
BIIB $401.71 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs